Figure 3.

Donor cells in recipients after transplantation of bulk TSA/AzaC-treated wt (A) or eGFP/bcl2 (B) neurosphere cells. Donor-specific FACS analysis of peripheral blood cells of nontransplanted CD45.2 and CD45.1 animals (panels 1 and 5) and of recipients receiving untreated (panels 2 and 6) or treated CD45.1 congenic wt or CD45.2 congenic eGFP/bcl2 neurosphere cells (panels 3 and 7). Animals receiving CD45.1 congenic or eGFP transgenic, CD45.2 congenic bone marrow cells are shown (panels 4 and 8). Recipient #154 is shown in panel 7. Percentages of cells positive for donor or lineage markers are shown. Also shown are summaries of the engraftment (%) in the peripheral blood by wt or eGFP/bcl2 neurosphere-derived cells. Numbers of chimerics per total number of analysed animals are given. Animals were analysed 1.5-2 months after transplantation. The results from wt and bulk eGFP/bcl2 neurosphere cell transplantations were from two and six independent experiments; 2/2 and 3/6 transplantations produced haematopoietic chimaeras.